The invention relates to a detergent composition comprising an enzyme and a boronic acid or borinic acid derivative which acts as a stabilizer for the enzyme in detergent compositions. Specific boronic acid inhibiters include benzofuran substituted boronic acids.

Patent
   5840677
Priority
Jul 09 1993
Filed
Jan 25 1996
Issued
Nov 24 1998
Expiry
Jun 22 2014
Assg.orig
Entity
Large
10
9
EXPIRED
1. A liquid composition comprising an enzyme and a boronic acid derivative enzyme stabilizer or borinic acid derivative enzyme stabilizer of the following formula: ##STR3## where R1 is (a) a substituted fused aromatic ring structure containing 14 or 18 carbon atoms in the ring;
(b) a substituted monocyclic heterocyclic ring structure containing up to 17 carbon atoms in the ring;
(c) a substituted fused aromatic heterocyclic ring structure containing up to 17 carbon atoms in the ring;
(d) a substituted monocyclic quinonone ring structure containing up to 18 carbon atoms in the ring;
(e) a substituted fused quinonone ring structure containing up to 18 carbon atoms in the ring; wherein
R2 has the formula: ##STR4## where X is the same or different and selected from hydrogen, C1 -C6 alkyl, substituted C1 -C6 alkyl, aryl, substituted aryl, hydroxy, hydroxyl derivative, halogen, amine, alkylated amine, amine derivative, nitro, thiol, thiol derivative, aldehyde, acid, acid salt, ester, sulfonate or phosphonate, and o, p and q may each be 0, 1, or 2; n and m may each be 0 or 1; R1 and R3 are independently one of a hydroxyl group, a substituted monocyclic ring structure, or a substituted dicyclic aromatic ring structure.
2. A liquid composition according to claim 1, wherein the enzyme stabilizer is benzofuran-2-boronic acid.
3. The liquid composition according to claim 1, wherein said composition is a detergent composition.
4. The liquid composition according to claim 1, wherein the enzyme is a protease.
5. A liquid composition according to claim 1, additionally comprising a detergent-compatible second enzyme, wherein said second enzyme is selected from the group consisting of an amylase, a lipase, a cellulase or a peroxidase or any mixture thereof.
6. The liquid composition according to claim 5, wherein the enzyme is a lipase.
7. The liquid composition according to claim 1, wherein said boronic acid or borinic acid derivative enzyme stabilizer is an alkali metal salt derivative.
8. The liquid composition according to claim 1, wherein said boronic or borinic acid derivative is added in an amount of up to 500 mM, preferably in an amount of 0.001-250 mM.
9. The liquid composition according to claim 8, wherein said boronic or borinic acid derivative is added in an amount of 0.005-100 mM.
10. The liquid composition according to claim 9, wherein said boronic or borinic acid derivative is added in an amount of 0.01-10 mM.

This application is a continuation of PCT/DK94/00249 filed Jun. 22, 1994, which is incorporated herein by reference.

This invention relates to a liquid composition containing an enzyme and an improved enzyme stabilizer.

Storage stability problems are well known with liquids containing enzyme(s). Especially in enzyme-containing liquid detergents a major problem, in particular if the detergent contains protease, is that of ensuring enzyme activity over time.

The prior art has dealt extensively with improving the storage stability, for example by adding a protease inhibitor.

Boric acid and boronic acids are known to reversibly inhibit proteolytic enzymes. A discussion of the inhibition of one serine protease, subtilisin, by boronic acid is provided in Molecular & Cellular Biochemistry 51, 1983, pp. 5-32.

Boronic acids have very different capacities as subtilisin inhibitors. Boronic acids containing only alkyl groups such as methyl, butyl or 2-cyclohexylethyl are poor inhibitors with methylboronic acid as the poorest inhibitor, whereas boronic acids bearing aromatic groups such as phenyl, 4-methoxyphenyl or 3,5-dichlorophenyl are very good inhibitors with 3,5-dichlorophenylboronic acid as a particularly effective one (see Keller et al, Biochem. Biophys. Res. Com. 176, 1991, pp. 401-405).

It is also claimed that aryl boronic acids which have a substitution at the 3-position relative to boron are unexpectedly good reversible protease inhibitors. Especially, acetamidobenzene boronic acid is claimed to be a superior inhibitor of proteolytic enzymes (see WO 92/19707).

The inhibition constant (Ki) is ordinarily used as a measure of capacity to inhibit enzyme activity, with a low Ki indicating a more potent inhibitor. However, it has earlier been found that the Ki values of boronic acids do not always tell how effective inhibitors they are (see for instance WO 92/19707).

In this invention it is surprisingly found that some special boronic and borinic acid derivatives have extraordinary good capacities as enzyme stabilizers.

Accordingly, the present invention relates to a liquid composition comprising an enzyme and a boronic acid or a borinic acid derivative enzyme stabilizer of the following formula: ##STR1## where R1 is an optionally substituted fused aromatic ring structure containing 14 or 18 carbon atoms in the ring, or an optionally substituted monocyclic or fused aromatic heterocyclic ring structure containing up to 17 carbon atoms in the ring, or an optionally substituted monocyclic or fused quinonoid ring structure containing up to 18 carbon atoms in the ring;

R2 has the formula: ##STR2## where X is the same or different and selected from hydrogen, C1 -C6 alkyl, substituted C1 -C6 alkyl, aryl, substituted aryl, hydroxy, hydroxyl derivative, halogen, amine, alkylated amine, amine derivative, nitro, thiol, thiol derivative, aldehyde, acid, acid salt, ester, sulfonate or phosphonate, and o,p and q may be the same or different and may each be 0,1 or 2; m and n may be the same or different and may each be 0 or 1; R3 is the same or different as R1 and selected from R1, or R3 is a hydroxyl group, or R1 and R3 are both optionally substituted monocyclic or dicyclic aromatic ring structures.

In this context optionally substituted ring structures mean that the substituents on the ring structure are freely chosen, but they are preferably selected from hydrogen, C1 -C6 alkyl, substituted C1 -C6 alkyl, aryl, substituted aryl, hydroxy, hydroxyl derivative, halogen, amine, alkylated amine, amine derivative, nitro, thiol, thiol derivative, aldehyde, acid, acid salt, ester, sulfonate or phosphonate.

Preparation of Boronic and Borinic Acid Derivatives

Boronic and borinic acid derivatives may be prepared using methods well known to those skilled in the art, for example by using one of the following methods:

a) Hydroboration of unsaturated materials, i.e. alkenes and alkynes, using either catecholborane (1,3,2-benzodioxaborole) or dichloroborane-dimethyl-sulphide complex as the hydroborating agent, for reference see H. C. Brown, S. K. Gupta in JACS 97, 1975, pp. 5249-5255 and H. C. Brown, N. Ravindran, S. U. Kuikarni in J. Org. Chem. 45, (1980), p. 384.

b) The reaction of a Grignard reagent with either tri-n-butylborate or trimethylborate, followed by hydrolysis of the boronic ester thus formed, for reference see F. R. Bean, J. R. Johnson in Jacs 54, 1932, pp. 4415-4425 and S. H. Dandegaonher, S. P. Ingleshwar in Journal of Shivasi University 6, 1932, pp. 11-13. Bromo-starting materials that are not commercially available may be prepared conveniently in two steps from the corresponding carboxylic acids by reduction with LiAlH4, followed by treatment with CBr4.

c) The reaction of an organolithium reagent with butylborate, for reference see S. O. Lauesson, pp. 387-395 in Thiophene Chemistry, part 7 and D. Florentin, B. Roques in C. R. Acad. Sc. Paris, t.270 (11 May 1970), pp. 1608-1610.

d) Borinic acid derivatives are prepared according to method b. However, the ratio of Grignard reagent to borate adopted is 2:1.

e) Any nuclear substitution or protection of functional groups is achieved by using standard methods well known to those skilled in the art.

Stabilizers

According to the invention the liquid composition may contain up to 500 mM of the stabilizer (the boronic or the borinic acid derivative), preferably the liquid composition may contain 0.001-250 mM of the stabilizer, more preferably the liquid composition may contain 0.005-100 mM of the stabilizer, most preferably the liquid composition may contain 0.01-10 mM of the stabilizer.

Enzymes

According to the invention the liquid composition contains at least one enzyme. The enzyme may be any commercially available enzyme, in particular an enzyme selected from the group consisting of proteases, amylases, lipases, cellulases or peroxidases or any mixture thereof. Mixtures of enzymes from the same class (e.g. lipases) are also included.

The amount of enzyme used in the composition varies according to the type of enzyme(s) and the use intended. If the liquid is a detergent liquid, the amount of each enzyme will typically be 0.2-40 μM, especially 0.4-20 μM (generally 5-1000 mg/l, especially 10-500 mg/l) calculated as pure enzyme protein.

Protease: Any protease suitable for use in a liquid composition can be used. Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically or genetically modified mutants are included. It may be a serine protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus, e.g. subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of commercial Bacillus subtilisins are Alcalase®, Savinase®, Esperase® and Durazym™ products of Novo Nordisk A/S. Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO 89/06270.

Amylase: Any amylase suitable for use in a liquid composition can be used. Suitable amylases include those of bacterial and fungal origin. Chemically or genetically modified mutants are included. Amylases include, for example, α-amylases obtained from a special strain of B. licheniformis, described in more detail in British Patent Specification No. 1,296,839. Particularly preferred is Termamyl®, available from Novo Nordisk A/S.

Lipase: Any lipase suitable for use in a liquid composition can be used. Suitable lipases include those of bacterial and fungal origin. Chemically or genetically modified mutants are included. Particularly preferred is lipase obtained by cloning the gene from Humicola lanuginosa and expressing the gene in Aspergillus orvzae, as described in EP 0 258 068, available under the trade mark Lipolase® from Novo Nordisk A/S.

Cellulase: Any cellulase suitable for use in a liquid composition can be used. Suitable cellulases include those of bacterial and fungal origin. Chemically or genetically modified mutants are included. Suitable cellulases are disclosed in U.S. Pat. No. 4,435,307. Particularly preferred is Celluzyme™ produced by a strain of Humicola insolens, available from Novo Nordisk A/S.

Peroxidase: Any peroxidase suitable for use in a liquid detergent composition can be used herein. Suitable peroxidases herein include those of plant, bacterial and fungal origin. Chemically or genetically modified mutants are included. Examples of suitable peroxidases are those derived from a strain of Coprinus. e.g. C. cinerius or C. macrorhizus, or from a strain of Bacillus, e.g. B. pumilus, particularly peroxidase according to PCT/DK90/00260.

Detergents

If the liquid composition of the invention is a detergent, it will beside enzyme(s) and stabilizer comprise a surfactant.

The liquid detergent may be aqueous, typically containing up to 70% of water and 0-30% of organic solvent, or nonaqueous.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS), alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

The detergent may contain 1-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst). The detergent may also be unbuilt, i.e. essentially free of detergent builder.

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC), poly(vinyl-pyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H2 O2 source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylethylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS). Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

The enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative as e.g. an aromatic borate ester, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. 7-11.

Particular forms of detergent compositions within the scope of the invention include:

1) An aqueous liquid detergent composition comprising

______________________________________
linear alkylbenzenesulfonate
15-21%
(calculated as acid)
alcohol ethoxylate 12-18%
(e.g. C12-15 alcohol, 7 EO or
C12-15 alcohol, 5 EO)
soap as fatty acid (e.g. oleic acid)
3-13%
alkenylsuccinic acid (C12-14)
0-13%
aminoethanol 8-18%
citric acid 2-8%
phosphonate 0-3%
polymers (e.g. PVP, PEG) 0-3%
borate (as B4 O7) 0-2%
ethanol 0-3%
propylene glycol 8-14%
enzymes 0-5%
minor ingredients 0-5%
(e.g. dispersants, suds suppressors,
perfume, optical brightener)
______________________________________

2) An aqueous structured liquid detergent composition comprising

______________________________________
linear alkylbenzenesulfonate
15-21%
(calculated as acid)
alcohol ethoxylate 3-9%
(e.g. C12-15 alcohol, 7 EO
or C12-15 alcohol, 5 EO)
soap as fatty acid (e.g. oleic acid)
3-10%
zeolite (as NaAlSiO4) 14-22%
potassium citrate 9-18%
borate (as B4 O7) 0-2%
carboxymethylcellulose 0-2%
polymers (e.g PEG, PVP) 0-3%
anchoring polymers as 0-3%
e.g. lauryl metharylate/acrylic acid copolymer;
molar ratio 25:1; MW 3800
glycerol 0-5%
enzymes 0-5%
minor ingredients 0-5%
(e.g. dispersants, suds suppressors, perfume,
optical brighteners)
______________________________________

3) An aqueous liquid detergent composition comprising

______________________________________
linear alkylbenzenesulfonate
15-23%
(calculated as acid)
alcohol ethoxysulfate 8-15%
(e.g. C12-15 alcohol, 2-3 EO)
alcohol ethoxylate 3-9%
(e.g. C12-15 alcohol, 7 EO
or C12-15 alcoho1, 5 EO)
soap as fatty acid (e.g. lauric acid)
0-3%
aminoethanol 1-5%
sodium citrate 5-10%
hydrotrope (e.g. sodium toluenesulfonate)
2-6%
borate (as B4 O7) 0-2%
carboxymethylcellulose 0-1%
ethanol 1-3%
propylene glycol 2-5%
enzymes 0-5%
minor ingredients (e.g. polymers, dispersants,
0-5%
perfume, optical brighteners)
______________________________________

4) An aqueous liquid detergent composition comprising

______________________________________
linear alkylbenzenesulfonate
20-32%
(calculated as acid)
alcohol ethoxylate 6-12%
(e.g. C12-15 alcohol, 7 EO
or C12-15 alcohol, 5 EO)
aminoethanol 2-6%
citric acid 8-14%
borate (as B4 O7) 1-3%
polymer (e.g. maleic/acrylic acid copolymer,
0-3%
anchoring polymers as e.g.
lauryl methacrylate/acrylic acid
copolymer and CMC)
glycerol 3-8%
enzymes 0-5%
minor ingredients (e.g. hydrotropes,
0-5%
dispersants, perfume, optical brighteners)
______________________________________

5) Detergent formulations as described in 1)-4) where the content of linear alkylbenzenesulfonate--or a part of it--is substituted by alkyl sulfate (C12 -C18).

6) Detergent formulations as described in 1)-5) which contain a stabilized or encapsulated peracid either as an additional component or as a substitute for already specified bleach systems.

7) Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant as e.g. linear alkoxylated primary alcohol, a builder system (e.g. phosphate), enzyme and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

Tests of Stabilizers

According to the invention the effectiveness of each stabilizer may be tested in one or more of the following three tests:

a) Storage Stability Test in Licuid Deterrent: Enzyme(s) and stabilizer are added to a liquid detergent formulation and stored at well defined conditions. The enzyme activity of each enzyme is determined as a function of time, e.g. after 0, 3, 7 and 14 days.

To calculate the inhibition efficiency from the storage stability date a reaction mechanism is proposed. The following reactions give a relatively simple, but yet plausible, mechanism for a liquid detergent containing protease (P), lipase (L), and inhibitor (I):

I) Autodigestion of protease:

P+P→DP +P

II) Denaturation of protease:

P→DP

III) Inhibition of protease:

P+I⇄PI

IV) Protease digestion of inhibited enzyme:

P+PI→P+DP +I

V) Denaturation of inhibited enzyme:

PI→DP +I

VI) Protease digestion of lipase:

P+L→P+DL

VII) Denaturation of lipase:

L→DL

where DP and DL are denatured (i.e. non-active) protease and lipase.

From these reactions three coupled differential equations are derived describing the deactivation of P, L and PI. The reaction rate constants are derived from storage stability data by the use of a parameter estimation method (Gauss-Newton with the Levenberg modification). The storage stability data give the concentration of (P+PI) and L as a function of time.

Reaction III is much faster than the other reactions and equilibrium is assumed in the calculations. Reaction IV is excluded from the system to reduce the number of parameters thereby describing the stability of the inhibited enzyme by only one reaction rate constant (from equation V).

In all experiments there is a large surplus of inhibitor molecules compared to protease molecules, i.e. a constant concentration of inhibitor (corresponding to the added amount of inhibitor) is a reasonable assumption.

The specific values of the reaction rate constants are somewhat sensitive to small variations in the data, but the sensitivity is reduced significantly by giving the results relatively to the value from Boric Acid. An improvement factor is thus derived: ##EQU1## IFI measures the inhibition efficiency given by the inhibition constants KI from reaction III.

b) The "Milk" Test: In this test the stabilizer to be tested is compared with a reference inhibitor (boric acid). The test is described in details below:

Preparation of "inhibitor" milk: 0.075 g of CaCl2 (dried fine-granular pure, Merck), 0.16 g of 3,3-dimethylglutaric acid (SIGMA) and 2.5 mmole of stabilizer/inhibitor are weighed out and dissolved in 50 ml of demineralised water. pH is adjusted to approx. 6.0 with NaOH. 6.0 g of skimmed milk powder (dehydrated, DIFCO Lab.) are weighed out in a 100 ml beaker, and the solution of salt+buffer+stabilizer/inhibitor is added. This mixture is stirred heavily for some minutes to be sure that all lumps, if any, are apart. Thereafter the mixture is stirred for 30 minutes. pH is adjusted to 6.50 with NaOH. Skimmed milk from a bottle can be used instead of powder. Use milk from the same bottle for all stabilizers/inhibitors in one run.

Preparation of the enzyme: Prepare a solution of approx. 30 KNPU/liter of Savinase® (available from Novo Nordisk A/S) in boric acid buffer (see below). The Savinase activity is determined relatively to an enzyme standard. A folder AF 220/1-GB describing the analytical method of determining the Savinase activity is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

Example: 1.0 g of 16 KNPU/g liquid Savinase is weighed out and 50 ml of boric acid buffer are added. The mixture is stirred for 15 minutes. 10 ml of this solution are filled into a 100 ml beaker, and boric acid buffer is added up to 100 ml. Thereafter the mixture is stirred for 15 minutes. Boric acid buffer: 2.5 g of boric acid (Merck) are dissolved in 500 ml of demineralised water. pH is adjusted to 9.0 with NaOH.

The curdling: 10.0 ml of stabilizer/inhibitor are added to a test tube. 3 test tubes of each stabilizer/inhibitor are made and placed in a 30°C water bath. The test tubes are left in the water bath for one hour. 1.00 ml of Savinase solution is added to the test tube and the stop-watch is started. The tube is mixed for 10 seconds on the "vibrator" and thereafter placed in the water bath. When the curdling starts the stop-watch is stopped. The deviation between the curdling time for the three test tubes should not be more than approx. 10 seconds. How and when the curdling starts must be learned in practice and the same person should curdle all samples. The curdling time for the reference inhibitor (boric acid) should be around 3-4 minutes (if the curdling time is longer, a stronger protease solution should be used). The curdling time is approx. linear proportional to 1/(protease activity). The result can be reported as an improvement factor IF defined by: (curdling time stabilizer)/(curdling time reference).

c) Determination of Ki : The inhibition constant Ki may be determined by using standard methods, for reference see Keller et al, Biochem. Biophys. Res. Com. 176, 1991, pp.401-405; J. Bieth in Bayer-Symposium "Proteinase Inhibitors", pp. 463-469, Springer-Verlag, 1974 and Lone Kierstein Hansen in "Determination of Specific Activities of Selected Detergent Proteases using Protease Activity, Molecular Weights, Kinetic Parameters and Inhibition Kinetics", PhD-report, Novo Nordisk A/S and University of Copenhagen, 1991.

The invention is further illustrated in the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

Preparation of 3-Thiopheneboronic Acid

3-Bromothiophene (0.043 m) in sodium dried ether (100 ml) was cooled to -60°C Butyllithium (30 ml of 1 M) was added rapidly. The mixture was then stirred for 3 minutes, thereafter tri-n-butyl borate (0.043 m) or trimethylborate (0.043 m) in sodium dried ether (25 ml) was added. The mixture was stirred for 4 hours and allowed to warm to room temperature. Thereafter the reaction mixture was treated with hydrochloric acid (1 M) and the ether layer was separated. The aqueous layer was extracted with ether (2 times 25 ml). The combined ether layers were extracted with sodium hydroxide (1 M). The alkaline solution was then acidified with hydrochloric acid (10%), thus precipitating the desired boronic acid. The boronic acid was isolated and then recrystallized from water/ethanol and allowed to dry in air.

C4 H5 BO2 S, mpt. 163°-164°C

Preparation of Diphenylborinic Acid

This was prepared using the above method. The Grignard reagent was prepared from bromobenzene and Magnesium turnings. However, two moles of Grignard reagent were used per one mole of tri-n-butylborate. The borinic acid so formed was isolated by reaction with ethanolamine thus yielding the diphenylborinic acid, ethanolamine complex ((C6 H5)2 BO.CH2 CH2 NH2), which is easier to handle. Mpt.192°-194°C

Determination of Ki

The inhibition constants Ki, for the inhibition of Alcalase and Savinase respectively, were determined using standard methods under the following conditions:

Substrate: Succinyl-Alanine-Alanine-Proline-Phenylalanine-para-nitro-anilide=SAAPFpNA (Sigma S-7388).

Buffer: 0.1 M Tris-HCl pH 8.6; 25°C

Enzyme concentration in assay

Alcalase: 1×10-10 -3×10-10 M

Savinase: 1-10-10 -3×10-10 M

The initial rate of substrate hydrolysis was determined at nine substrate concenterations in the range of 0.01 to 2 mM using a Cobas Fara automated spectrophotometer. The kinetic parameters Vmax and Km were determined using ENZFITTER (a non-linear regression data analysis program). kcat was calculated from the equation Vmax =kcat X[Eo ]. The concentration of active enzyme [Eo ] was determined by active site titration using tight-binding protein proteinase inhibitors. The inhibition constant Ki was calculated from plots of Km /kcat as a function of the concentration of inhibitor. The inhibitors were assumed to be 100% pure and the molar concentrations were determined using weighing numbers and molecular weights.

The results of the inhibition constants Ki of the boronic and borinic acid derivative enzyme stabilizers tested are listed below.

TABLE 1
______________________________________
The Inhibition Constants for the Inhibition of Alcalase and
Savinase by Different Boronic and Borinic Acid Derivatives
Boric Acid are included for Comparison.
Ki Ki
Inhibitor Alcalase Savinase
______________________________________
Boric acid 30 mM 20 mM
Thiophene-3- 2 mM 2 mM
boronic acid
Thiophene-2- 2 mM 2 mM
boronic acid
4-Methylthiophene-
1.8 mM 3 mM
2-boronic acid
5-Ethylthiophene-
0.7 mM 0.9 mM
2-boronic acid
5-Methylthiophene-
2 mM 3 mM
2-boronic acid
5-Bromothiophene-
0.4 mM 0.2 mM
2-boronic acid
5-Chlorothiophene-
0.3 mM 0.2 mM
2-boronic acid
Dibenzothiophene-
0.9 mM 1.5 mM
1-boronic acid
Dibenzofuran-1- 1.1 mM 1.5 mM
boronic acid
Dibenzofuran-4- 0.9 mM 1.1 mM
boronic acid
Picoline-2-boronic
3 mM 4 mM
acid
Diphenylborinic 2 mM 4 mM
acid (ethanolamine
complex)
5-Methoxythio- 2 mM 1 mM
phene-2-boronic
acid
Thionaphthrene-1-
2 mM 3 mM
boronic acid
Furan-2-boronic 3 mM 4 mM
acid
Furan-3-boronic 10 mM 7 mM
acid
2,5-dimethyl- 3 mM 6 mM
thiophene-3-boro-
nic acid
Benzofuran-1-boro-
1 mM 0.8 mM
nic acid
3-Methoxythio- 3 mM 1.2 mM
phene-2-boronic
acid
5-n-Propyl- 1.5 mM 3 mM
thiophene-2-
boronic acid
5-Methoxyfuran-2-
2 mM 3 mM
boronic acid
3-Bromothiophene-
2 mM 2 mM
2-boronic acid
5-Ethylfuran-2- 2 mM 3 mM
boronic acid
4-Carbazole ethyl
1 mM 2 mM
boronic acid
______________________________________

Storage Stability Test in Liquid Detergent

Different boronic and borinic acid derivative enzyme stabilizers were also tested in storage stability tests in liquid detergents using the method described previously under the following conditions:

______________________________________
Detergent base (US-type)
% wt (as pure components)
______________________________________
Nansa 1169/p 10.3 (Linear Alkylbenzene Sulfonate, LAS)
Berol 452 3.5 (Alkyl Ether Sulfate, AES)
Oleic acid 0.5
Coconut fatty acid
0.5
Dobanol 25-7 6.4 (Alcohol Ethoxylate, AEO)
Sodium xylene sulfonate
5.1
Ethanol 0.7
MPG 2.7 (Mono Propylene Glycol)
Glycerol 0.5
Sodium sulfate
0.4
Sodium carbonate
2.7
Sodium citrate
4.4
Citric acid 1.5
Water 60.8
Enzyme dosage:
1% w/w Savinase (KNPU/g) +
1% w/w Lipolase (100 KLU/g)
Enzyme Stabilizer Dosage:
5 mmole/kg (for boric acid 160 mmole/kg)
Storage: 0, 3, 7 and 14 days at 30°C
______________________________________

The results of the inhibition effectiveness IFI of the boronic and borinic acid derivative enzyme stabilizers tested are listed below.

TABLE 2
______________________________________
Different Boronic and Borinic Derivatives Enzyme Stabilizers
and the Corresponding IFI. Boric Acid is Included for Comparison.
Inhibitor Improvement factor IFI
______________________________________
Boric acid 1
Thiophene-2-boronic acid
72
Thiophene-3-boronic acid
63
4-Methylthiophene-2-
4
boronic acid
5-Ethylthiophene-2-
66
boronic acid
5-Bromothiophene-2-
124
boronic acid
5-Chlorothiophene-2-
123
boronic acid
Dibenzothiophene-1-
12
boronic acid
Dibenzofuran-1- 9
boronic acid
5-Methylthiophene-2-
12
boronic acid
5-Methoxythiophene-2-
14
boronic acid
Furan-2-boronic acid
13
Dimethylthiophene-3-
7
boronic acid
Furan-3-boronic acid
32
3-Methoxythiophene-2-
8
boronic acid
Benzofuran-2-boronic acid
190
Thionaphthrene-1- 20
boronic acid
Dibenzofuran-4-boronic
19
acid
______________________________________

Comparing the reslults of Table 1 with the results of Table 2 it seems that the effect of a boronic or a borinic acid stabilizer in a detergent can be predicted from the results obtained in buffer systems and vice versa.

Nielsen, Lone Kierstein, Deane-Wray, Allison

Patent Priority Assignee Title
10590368, Mar 27 2007 NOVOZYMES A S Stable enzyme solutions and method of manufacturing
11827866, Mar 27 2007 Novozymes A/S Stable enzyme solutions and method of manufacturing
5968887, Jul 09 1993 NOVOZYMES A S Boronic acid or borinic acid derivatives as enzyme stabilizers
6858592, Jun 29 2001 Genzyme Corporation Aryl boronic acids for treating obesity
6919382, Aug 31 2000 Governors of the University of Alberta, The Preparation and uses of conjugated solid supports for boronic acids
7041280, Jun 29 2001 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
7049304, Jun 29 2001 Genzyme Corporation Aryl boronic acids for treating obesity
7456156, Jun 29 2001 Genzyme Corporation Aryl boronic acids for treating obesity
9242222, Apr 19 2010 The University of Toledo Aldose-ketose transformation for separation and/or chemical conversion of C6 and C5 sugars from biomass materials
9528104, Jan 04 2008 The University of Toledo System for simultaneous isomerization and fermentation of sugars
Patent Priority Assignee Title
5039446, Jul 20 1987 GENECOR INTERNATIONAL, INC , 4 CAMBRIDGE PLACE, 1870 WINTON ROAD S , ROCHESTER, NY, A CORP OF DE Liquid detergent with stabilized enzyme
5354491, Aug 14 1992 The Procter & Gamble Company; Procter & Gamble Company, The Liquid detergent compositions containing protease and certain β-aminoalkylboronic acids and esters
5422030, Apr 30 1991 Procter & Gamble Company, The Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
5431842, Nov 05 1993 The Procter & Gamble Company; Procter & Gamble Company, The Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
5472628, Apr 30 1991 The Procter & Gamble Company Liquid detergents with an aryl acid for inhibition of proteolytic enzyme
5476608, Dec 04 1991 The Procter & Gamble Company Liquid laundry detergents with citric acid, cellulase, and boricdiol complex to inhibit proteolytic enzyme
5488157, Aug 14 1992 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
EP478050A1,
WO9219707,
//////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 11 1995DEANE-WRAY, ALLISONBORAX CONSOLIDATED LTD CORRECTIVE ASSIGNMENT TO ADD AN ADDITIONAL ASSIGNEE AN ASSIGNMENT WAS PREVIOUSLY RECORDED AT REEL 7906, FRAME 0479 0086350103 pdf
Dec 11 1995NIELSEN, LONE KIERSTEINNovo Nordisk A SASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079060479 pdf
Dec 11 1995DEANE-WRAY, ALLISONNovo Nordisk A SCORRECTIVE ASSIGNMENT TO ADD AN ADDITIONAL ASSIGNEE AN ASSIGNMENT WAS PREVIOUSLY RECORDED AT REEL 7906, FRAME 0479 0086350103 pdf
Jan 03 1996NIELSEN, LONE KIERSTEINNovo Nordisk A SCORRECTIVE ASSIGNMENT TO ADD AN ADDITIONAL ASSIGNEE AN ASSIGNMENT WAS PREVIOUSLY RECORDED AT REEL 7906, FRAME 0479 0086350103 pdf
Jan 03 1996DEANE-WRAY, ALLISONNovo Nordisk A SASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0079060479 pdf
Jan 03 1996NIELSEN, LONE KIERSTEINBORAX CONSOLIDATED LTD CORRECTIVE ASSIGNMENT TO ADD AN ADDITIONAL ASSIGNEE AN ASSIGNMENT WAS PREVIOUSLY RECORDED AT REEL 7906, FRAME 0479 0086350103 pdf
Jan 25 1996Novo Nordisk A/S(assignment on the face of the patent)
Jan 25 1996Borax Consolidated Ltd.(assignment on the face of the patent)
Aug 01 1997BORAX CONSOLIDATED LIMITEDNovo Nordisk A SASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0086950823 pdf
Oct 29 2001Novo Nordisk A SNOVOZYMES A SASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0124630868 pdf
Date Maintenance Fee Events
May 22 2002M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Jun 14 2006REM: Maintenance Fee Reminder Mailed.
Nov 24 2006EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Nov 24 20014 years fee payment window open
May 24 20026 months grace period start (w surcharge)
Nov 24 2002patent expiry (for year 4)
Nov 24 20042 years to revive unintentionally abandoned end. (for year 4)
Nov 24 20058 years fee payment window open
May 24 20066 months grace period start (w surcharge)
Nov 24 2006patent expiry (for year 8)
Nov 24 20082 years to revive unintentionally abandoned end. (for year 8)
Nov 24 200912 years fee payment window open
May 24 20106 months grace period start (w surcharge)
Nov 24 2010patent expiry (for year 12)
Nov 24 20122 years to revive unintentionally abandoned end. (for year 12)